Revenue
$213.60M
Fiscal year ended 2026-06-30Operating income
-$17.74M
Fiscal year ended 2026-06-30Free cash flow
-$4.39M
Fiscal year ended 2026-06-30SI-BONE, Inc. (SIBN) reported revenue of $213.60M and net income of -$14.63M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from SI-BONE, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $213.60M |
| Cost of revenue | $43.73M |
| Gross profit | $169.87M |
| Operating income | -$17.74M |
| Net income | -$14.63M |
| Research & development | $18.02M |
| Weighted-average diluted shares | Unavailable |
| Pretax income | Unavailable |
| Income tax expense | $0 |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $169.60M |
| General & administrative | $40.00M |
| Selling & marketing | $129.59M |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | $33.13M |
| Total assets | $248.76M |
| Current assets | $219.91M |
| Total liabilities | $66.41M |
| Current liabilities | $24.04M |
| Total equity incl. NCI | $182.35M |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $38.39M |
| Accounts receivable | $31.18M |
| Goodwill | Unavailable |
| Long-term debt | $35.63M |
| Accounts payable | $8.54M |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | $2.48M |
| Capital expenditures | $6.86M |
| Investing cash flow | -$5.97M |
| Financing cash flow | $2.70M |
| Net change in cash | -$1.02M |
| Stock-based compensation | $24.21M |
| Common dividends paid | Unavailable |
| Common share repurchases | Unavailable |
| Depreciation & amortization | $6.42M |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | -$4.39M |
| Gross margin | 79.5% |
| Operating margin | -8.3% |
| FCF margin | -2.1% |
| SBC / revenue | 11.3% |
| Current ratio | 9.15x |
| Revenue YoY growth | 15.3% |
| Net margin | -6.9% |
| R&D / revenue | 8.4% |
| CapEx / revenue | 3.2% |
| Long-term debt / equity | 0.20x |
| Effective tax rate | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SIBN in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-04View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-05View SEC filing
10-Q · Filed 2025-05-06View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.